Degarelix Acetate

醋酸地加瑞克

Report date: 2022/05/18 17:41:30
NME

Base Information

Drug NameDegarelix Acetate
Drug Alias Namedegarelixum地加瑞克GonaxFirmagonUglypeptide-1 +[7] 
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionGonadotropin-releasing hormone receptor antagonists
TargetsGonadotropin-releasing hormone receptor
Therapy Area/IndicationsHormone-Sensitive Prostate NeoplasmsLower Urinary Tract SymptomsHeart Diseases +[8] 
Global Approved IndicationsProstatic Neoplasms
Approved Indications in ChinaProstatic Neoplasms
Original Approved Country/TerritoryUnited States
Original Approved Date2008/12/24
Country/TerritoryFormer Serbia and MontenegroCzechiaBelgium +[35] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesFerring Bv
China Registration ClassN/A

Develop Information

Active CompaniesFerring BvPfizer IncAstellas Pharma Inc +[5] 
Inactive CompaniesFerring Pharmaceuticals Korea Co LtdUniversity Of CambridgeAssisting Nature Inc +[7] 
Active IndicationsProstatic NeoplasmsAdenocarcinoma
Inactive IndicationsHormone-Sensitive Prostate NeoplasmsLower Urinary Tract SymptomsHeart Diseases +[6] 

Other Information

ATC CodeL02BX02
Related LinksN/A